A popular marketer of handheld ultrasound devices has won FDA approval for an AI-enabled B-line quantification tool for use with patients suspected of having compromised lung function.

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

Abhinhav Jha, PhD, discusses his plans for a $314,807 NIH grant to explore the ethics of AI in imaging given its inherent uncertainties.  

Various scenarios within medical diagnostics are among the AI use cases that an official European watchdog has flagged as a potential source of hazards to fundamental human rights.

The researchers say their AI technique produces an 11% boost in accuracy over that supplied by other contemporary flu forecasting systems.

AI is a key part of the plan as two groups with little in common come together over health disparities that have only been worsened by the COVID-19 pandemic.

‘We find that two factors reduce lay judgment of liability: following standard care and following the recommendation of AI tools.’

AI will not earn a place in the daily practice of medicine until its developers definitively answer some pressing questions on fitness and appropriateness.